S-1/A: Propanc Biopharma Files Amended S-1 for Public Offering Amidst Soaring Losses and Going Concern Doubts

Propanc Biopharma, Inc. has filed an amended S-1 registration statement to offer 1,000,000 shares of common stock and allow for the resale of 3,091,500 shares by existing stockholders, as the company grapples with a significantly increased net loss of $54.85 million and substantial doubt about its ability to continue as a going concern.

Summary

• Propanc Biopharma, Inc. is a development-stage healthcare company focused on new cancer treatments, with its lead product candidate, PRP, currently in preclinical development.
• The company is seeking to raise approximately $4.6 million in net proceeds from a public offering of 1,000,000 shares of common stock at an assumed price of $5.00 per share, contingent on its listing on the Nasdaq Capital Market.
• An additional 3,091,500 shares held by certain selling stockholders are registered for potential resale, from which the company will not receive any proceeds.
• For the nine months ended March 31, 2025, the company reported a net loss of $54,851,839, a drastic increase from $1,461,950 for the same period in 2024.
• Administration expenses surged to $53,442,499 for the nine months ended March 31, 2025, primarily due to $51,333,000 in stock-based compensation to officers, employees, directors, and consultants, and $1,505,115 for stock-based consulting and legal services.
• The company's accumulated deficit reached $121,550,059 as of March 31, 2025, up from $66,698,220 as of June 30, 2024.
• Cash on hand as of March 31, 2025, was $50,760, with net cash used in operating activities of $377,982 for the nine months ended March 31, 2025.
• The company has substantial doubt about its ability to continue as a going concern due to a lack of revenue, recurring losses, and negative cash flows, necessitating additional capital.
• Several convertible notes and loans are currently in default, including a Crown Bridge Note ($65,280 principal, $52,918 accrued interest), one ONE44 note ($104,460 principal), and four GS Capital notes ($121,650 total principal), all accruing default interest at 15% or 24% per annum.
• Propanc Biopharma holds 85 granted, allowed, or accepted patents and 5 patent applications related to its proenzyme cancer treatment, PRP, and has Orphan Drug Designation for pancreatic cancer from the FDA.
• The company has implemented a 1-for-60,000 reverse stock split, effective January 29, 2025, and previously a 1-for-1,000 reverse stock split effective May 1, 2023.
• James Nathanielsz, the CEO and CFO, maintains majority voting control through Series B Preferred Stock, and the company will operate as a controlled company under Nasdaq rules, though it does not intend to avail itself of all exemptions.

Sentiment

Score: 1

Explanation: The company faces severe financial distress, evidenced by a massive increase in net loss, a rapidly growing accumulated deficit, and explicit 'substantial doubt about its ability to continue as a going concern.' While attempting a public offering, its current financial state, high burn rate from non-cash compensation, and numerous defaulted debts indicate extreme risk and a highly speculative investment.

Positives

• The company has applied to list its common stock on the Nasdaq Capital Market, which could improve liquidity and investor visibility if approved.
• Propanc Biopharma holds a significant intellectual property portfolio with 85 granted, allowed, or accepted patents and 5 patent applications for its proenzyme cancer treatment, PRP.
• PRP has received Orphan Drug Designation status from the FDA for the treatment of pancreatic cancer, which offers developmental incentives like protocol assistance, potential research grants, waiver of future application fees, and tax credits.
• The company benefits from a 43.5% cash back benefit from overseas research and development expenses through a Certificate for Advance Overseas Finding from the Board of Innovation and Science Australia.
• Net cash used in operating activities decreased to $377,982 for the nine months ended March 31, 2025, compared to $675,152 for the same period in 2024, indicating a reduction in operational cash burn, albeit still negative.

Negatives

• The company reported a net loss of $54,851,839 for the nine months ended March 31, 2025, a substantial increase from $1,461,950 in the prior year period, driven primarily by a massive increase in stock-based compensation.
• Propanc Biopharma has an accumulated deficit of $121,550,059 as of March 31, 2025, and has experienced negative cash flows from operations since inception, raising substantial doubt about its ability to continue as a going concern.
• The company is in default under certain loans payable, notes payable, and convertible notes totaling approximately $552,000, with some accruing high default interest rates (15% to 24% per annum).
• Research and development expenses decreased to $170,199 for the nine months ended March 31, 2025, from $195,712 in the prior year, primarily due to cost-cutting measures necessitated by a lack of working capital funding, which could hinder product development progress.
• The dual role of James Nathanielsz as Chief Executive Officer and Chief Financial Officer presents risks related to limited financial oversight, increased workload, potential oversight gaps, and corporate governance concerns.
• Material weaknesses in internal control over financial reporting have been identified, including a lack of written documentation, insufficient segregation of duties, and absence of an independent audit committee, which could lead to inaccurate financial reporting.
• The company's product candidate, PRP, remains in early preclinical development, and commercial viability is uncertain, with expectations of several years before potential commercialization, if ever.
• The denial of Orphan Drug Designation for ovarian cancer due to prevalence exceeding the threshold limits potential market advantages for PRP in that indication.

Risks

• PRP remains in the early stages of development and may never become commercially viable, leading to a potential loss of investment.
• PRP may cause undesirable side effects that could negatively impact clinical trial results, limit its use, hinder further development, subject the company to product liability claims, and make commercialization difficult.
• Successful development of products is uncertain, and failure in clinical trials or regulatory approvals could materially harm results of operations.
• Clinical trials of PRP could be delayed or unsuccessful due to various factors, including patient enrollment issues, third-party contractor failures, or unforeseen side effects.
• Failure to obtain regulatory approval in jurisdictions outside the U.S. will prevent the company from marketing PRP in those regions.
• Inability to establish sales and marketing capabilities or secure third-party agreements for these functions could impede successful commercialization.
• The company faces substantial competition from major pharmaceutical and biotechnology companies, which may develop more effective, safer, or less costly products.
• Even if PRP is commercialized, obtaining approval for reimbursement and favorable pricing regulations from third-party payors is uncertain and could harm the business.
• Geopolitical conflicts, trade restrictions, and tariffs could adversely affect business, financial condition, and results of operations by increasing costs, disrupting supply chains, or limiting market access.
• The company's ability to continue as a going concern is in substantial doubt without obtaining adequate new debt or equity financings.
• Inability to remain in compliance with financial or other covenants in debt instruments could lead to default and creditors exercising rights over company assets.
• Significant losses are expected for the foreseeable future, and profitability may never be achieved or maintained, decreasing company value and impairing capital raising ability.
• Reliance on substantial debt financing convertible into common stock poses a risk of material adverse effect and negative price impact on the stock due to potential dilution from conversions at a discount to market prices.
• Raising additional capital will cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• The accounting method for convertible debt securities that may be settled in cash could have a material adverse effect on reported financial results and diluted EPS.
• Maintaining cash in Australian financial institutions exposes the company to uninsured amounts beyond AUD $250,000.
• Fluctuations in currency exchange rates may adversely impact cash flows and earnings.
• The limited public market for common stock on OTC Pink may result in unfavorable stock price and liquidity, and the designation as a 'penny stock' could further limit liquidity.
• Directors and officers currently control the company, limiting new investors' ability to elect directors or influence policies.
• Future sales and issuances of common stock or rights to purchase could result in additional dilution and cause stock price decline.
• Issuance of additional preferred stock without stockholder approval could make it more difficult for a third party to acquire the company and depress stock price.
• The company intends to retain earnings for business development, so stockholders are unlikely to receive dividends, relying solely on capital appreciation.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited by Section 382 of the Internal Revenue Code.
• As a smaller reporting company, scaled disclosure requirements may make it challenging for investors to analyze financial prospects.
• A large number of shares may be sold in the market following the offering, potentially depressing the market price.
• The market price of common stock may continue to be highly volatile due to various factors beyond the company's control.
• Dependence on collaborations with third parties for development and commercialization of PRP carries risks of unsuccessfulness or limited control.
• Reliance on a single manufacturer for PRP creates supply risks and potential adverse effects on profit margins.
• Failure to comply with intellectual property licenses could lead to loss of important license rights.
• Inability to obtain and maintain patent protection or sufficiently broad patent scope could allow competitors to commercialize similar products.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Third parties may allege infringement of their intellectual property rights, leading to uncertain outcomes and material adverse effects.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• Failure to obtain, or delays in obtaining, required regulatory approvals will materially impair revenue generation.
• PRP or any approved product could be subject to restrictions or withdrawal from the market, and the company may face penalties for non-compliance with regulatory requirements.
• Future relationships with customers and third-party payors will be subject to anti-kickback, fraud, and abuse laws, potentially exposing the company to sanctions.
• Recently enacted and future legislation, particularly in the U.S., may increase the difficulty and cost of obtaining marketing approval and affect pricing.
• Future success depends on retaining key management and attracting/retaining qualified personnel.
• Difficulties in managing anticipated growth could disrupt operations.
• Identified material weaknesses in internal control over financial reporting, if not remediated, could result in material misstatements and negatively affect stock price.
• Operating as a public company will incur significant increased costs.
• Judgments obtained against the company may not be enforceable due to assets and key personnel being located outside the U.S.

Future Outlook

Propanc Biopharma plans to use the net proceeds from the public offering primarily for working capital and general corporate purposes. The company intends to initiate a Phase Ib First-In-Human (FIH) study for its lead product candidate, PRP, in advanced cancer patients, evaluating safety, pharmacokinetics, and anti-tumor efficacy, with a hope to complete it within twelve months thereafter. Further plans include developing PRP for early-stage cancer and pre-cancerous diseases, and as a preventative measure. The company also hopes to continue and expand its R&D activities and will need substantial additional funding to progress PRP into clinical trials, seek regulatory approvals, and establish commercialization infrastructure.

Management Comments

• "We believe that our existing cash and cash equivalents, along with the net proceeds from this offering, together with interest on cash balances, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next twelve (12) to eighteen (18) months."
• "Management is currently seeking additional funds, primarily through the issuance of equity and/or debt securities for cash to operate our business."
• "We hope to increase the chief financial officer's role from part-time to full-time as the next step in building out our accounting department."
• "Further research and development collaborations are currently under negotiation with the University of Jan and other contract research organizations in preparation for upcoming available working capital for future research and development expenses."

Industry Context

Propanc Biopharma operates in the highly competitive biotechnology and pharmaceutical industries, characterized by continuous technological advancement. The company faces competition from major pharmaceutical and biotechnology companies, academic institutions, and research organizations globally. Its lead product candidate, PRP, aims to treat pancreatic, ovarian, and colorectal cancer, competing with established therapies and numerous products in clinical development. The industry is also subject to extensive and varying regulatory requirements across different countries, impacting development, approval, pricing, and reimbursement.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.
• The SEC filed a complaint against Crown Bridge (a former convertible note lender) in August 2022 due to its violation of Section 15(a)(1) of the Exchange Act, leading Crown Bridge to surrender all conversion rights in its notes held by the company.
• The company incurred a $30,000 penalty from the IRS for non-timely filing of informational Form 5471 for the years 2012 through 2014, plus accrued interest. The company is current on all subsequent filings.

Related Party Transactions

• The company leases its principal executive offices from North Horizon Pty Ltd., a related party owned and directed by Mr. James Nathanielsz (CEO, CFO, Director) and his wife, Sylvia Nathanielsz. Total rent payable to this entity was $124,976 USD as of March 31, 2025.
• Loans payable from related parties amounted to $366,029 as of March 31, 2025, including loans from an institutional investor affiliated with director Josef Zelinger, some of which are payable on demand and bear no interest, while others have interest rates of 12% (defaulting to 18%).
• A long-term loan payable from a related party (affiliated with Josef Zelinger) amounted to $93,913 (net of discount) as of March 31, 2025, with a principal of $153,256 AUD ($10% interest, 3-year term ending July 5, 2026), and warrants issued in connection with this loan.
• The company owed its former director $0 as of March 31, 2025, as outstanding loans and expenses totaling $74,395 were settled on January 23, 2025, by issuing 30,000 shares of common stock valued at $375,000, resulting in a loss on extinguishment of debt of $300,605.
• James Nathanielsz (CEO, CFO) receives an annual base salary of $600,000 AUD ($414,900 USD) and a discretionary bonus. He also receives a monthly contribution to his pension and a vehicle allowance. Accrued salaries for management totaled $122,280 USD as of March 31, 2025.
• Dr. Julian Kenyon (Chief Scientific Officer, Director) receives an annual salary of $54,000 AUD ($41,580 USD) for his services.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the public offering and potential future conversions of outstanding convertible debt, which are convertible at discounts to market prices. Existing shareholders have already experienced substantial dilution from previous stock splits (1:1,000 and 1:60,000 reverse splits) and stock issuances for services and debt exchanges. The 'going concern' doubt poses a high risk of losing their entire investment.
• **Employees**: The company's financial instability and cost-cutting measures (e.g., reduced R&D expenses) could impact job security and future compensation, despite recent large stock-based compensation grants to officers and employees.
• **Lenders**: Several lenders holding convertible notes and loans are currently in default, indicating a high risk of non-repayment in cash and forcing conversion into equity at potentially unfavorable terms, or facing significant losses on their investments.
• **Customers/Patients (Future)**: The slow progress of PRP through preclinical and early clinical stages, coupled with financial constraints, means that potential new cancer treatments may be significantly delayed or never reach commercialization, impacting future patient access to these therapies.
• **Suppliers/Consultants**: Some vendors and consultants have received common stock in exchange for payment of outstanding accounts payable or for future services, indicating the company's reliance on non-cash settlements due to liquidity issues, which could affect future willingness of suppliers to extend credit or services.

Next Steps

• Initiate a Phase Ib First-In-Human (FIH) study in patients with advanced solid tumors to evaluate the safety, pharmacokinetics, and anti-tumor efficacy of PRP, with a goal to complete it within twelve months.
• Continue and expand research and development activities, including negotiating further collaborations with the University of Jan and other contract research organizations.
• Seek regulatory approvals for PRP in the U.S., UK, Europe, Australia, and/or other countries.
• Establish or contract for a sales and marketing infrastructure if PRP or any other product candidate receives marketing approval.
• Remediate identified material weaknesses in internal control over financial reporting by establishing an audit committee, adding experienced accounting and financial personnel, and retaining third-party consultants.
• Increase the Chief Financial Officer's role from part-time to full-time, subject to sufficient capital.

Key Dates

Recommendation

Keywords

Biopharma, Cancer Treatment, Preclinical Development, Oncology, Proenzymes, PRP, Public Offering, Nasdaq Listing, SEC Filing, S-1/A, Orphan Drug Designation, Intellectual Property, Convertible Debt, Going Concern, Stock-Based Compensation, Reverse Stock Split, Corporate Governance, Risk Management